Altered MEF2C regulation has been implicated as driver of cancer development [40], and it acts as an oncogene for immature T-cell acute lymphoblastic leukaemia [41], myeloid leukaemia [42], hepatocellular carcinoma [43], and pancreatic ductal adenocarcinoma [44]. This evidence concerns the gene MEF2C and hepatocellular carcinoma.